drugset / Trial / NCT00357773

Efficacy and Safety of T1225 1.5% Versus Tobramycin 0.3 % in the Treatment of Purulent Bacterial Conjunctivitis

NCT00357773

Phase 3 Completed Laboratoires Thea
RandomizedParallel-groupSingle-blindTreatment

Summary

To demonstrate the efficacy of T1225 1.5% eye drops, in comparison to reference product, for the treatment of purulent bacterial conjunctivitis, and to assess the safety

Timeline

Start
2004-05
Primary completion
Completion
2005-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Azithromycin Small molecule 1.5 % Other